Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib in Combination With Darolutamide in mCRPC
NCT06190899Phase 2Recruiting
- Sponsor
- Celcuity Inc.
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of gedatolisib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Celcuity Inc.. Started Jan 2024; status: recruiting.
02
Drugs
gedatolisib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06190899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190899.